TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet

Abstract Toll‐like receptor‐7 (TLR7) activation promotes autoimmunity, and metabolic syndrome (MetS) is a common comorbidity in patients with autoimmune disease. We previously demonstrated hyperinsulinemia in TLR7 agonist imiquimod (IMQ)‐treated, high‐fat diet (HFD)‐fed female C57BL/6 mice. Since mo...

Full description

Bibliographic Details
Main Authors: Rahul M. Kakalij, Del L. Dsouza, LiGyeom Ha, Erika I. Boesen
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Physiological Reports
Subjects:
Online Access:https://doi.org/10.14814/phy2.15949
_version_ 1797306779215855616
author Rahul M. Kakalij
Del L. Dsouza
LiGyeom Ha
Erika I. Boesen
author_facet Rahul M. Kakalij
Del L. Dsouza
LiGyeom Ha
Erika I. Boesen
author_sort Rahul M. Kakalij
collection DOAJ
description Abstract Toll‐like receptor‐7 (TLR7) activation promotes autoimmunity, and metabolic syndrome (MetS) is a common comorbidity in patients with autoimmune disease. We previously demonstrated hyperinsulinemia in TLR7 agonist imiquimod (IMQ)‐treated, high‐fat diet (HFD)‐fed female C57BL/6 mice. Since mouse strains differ in susceptibility to MetS and target organ damage, this study investigated whether 12 weeks of exposure to HFD and IMQ promoted MetS, autoimmunity, and target organ damage in female FVB/N mice. Supporting early‐stage autoimmunity, spleen‐to‐tibia ratio, and anti‐nuclear antibodies (ANA) were significantly increased by IMQ. No significant effect of IMQ on urinary albumin excretion or left ventricular hypertrophy was observed. HFD increased liver‐to‐tibia ratio, which was further exacerbated by IMQ. HFD increased fasting blood glucose levels at the end of 12 weeks, but there was no significant effect of IMQ treatment on fasting blood glucose levels at 6 or 12 weeks of treatment. However, oral glucose tolerance testing at 12 weeks revealed impaired glucose tolerance in HFD‐fed mice compared to control diet mice together with IMQ treatment exacerbating the impairment. Accordingly, these data suggest TLR7 activation also exacerbates HFD‐induced dysregulation of glucose handling FVB/N mice, supporting the possibility that endogenous TLR7 activation may contribute to dysglycemia in patients with autoimmune disease.
first_indexed 2024-03-08T00:46:45Z
format Article
id doaj.art-15d4059c270b4e5b9b15242e94b58492
institution Directory Open Access Journal
issn 2051-817X
language English
last_indexed 2024-03-08T00:46:45Z
publishDate 2024-02-01
publisher Wiley
record_format Article
series Physiological Reports
spelling doaj.art-15d4059c270b4e5b9b15242e94b584922024-02-15T06:28:36ZengWileyPhysiological Reports2051-817X2024-02-01123n/an/a10.14814/phy2.15949TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat dietRahul M. Kakalij0Del L. Dsouza1LiGyeom Ha2Erika I. Boesen3Department of Cellular & Integrative Physiology University of Nebraska Medical Center Omaha Nebraska USADepartment of Cellular & Integrative Physiology University of Nebraska Medical Center Omaha Nebraska USADepartment of Cellular & Integrative Physiology University of Nebraska Medical Center Omaha Nebraska USADepartment of Cellular & Integrative Physiology University of Nebraska Medical Center Omaha Nebraska USAAbstract Toll‐like receptor‐7 (TLR7) activation promotes autoimmunity, and metabolic syndrome (MetS) is a common comorbidity in patients with autoimmune disease. We previously demonstrated hyperinsulinemia in TLR7 agonist imiquimod (IMQ)‐treated, high‐fat diet (HFD)‐fed female C57BL/6 mice. Since mouse strains differ in susceptibility to MetS and target organ damage, this study investigated whether 12 weeks of exposure to HFD and IMQ promoted MetS, autoimmunity, and target organ damage in female FVB/N mice. Supporting early‐stage autoimmunity, spleen‐to‐tibia ratio, and anti‐nuclear antibodies (ANA) were significantly increased by IMQ. No significant effect of IMQ on urinary albumin excretion or left ventricular hypertrophy was observed. HFD increased liver‐to‐tibia ratio, which was further exacerbated by IMQ. HFD increased fasting blood glucose levels at the end of 12 weeks, but there was no significant effect of IMQ treatment on fasting blood glucose levels at 6 or 12 weeks of treatment. However, oral glucose tolerance testing at 12 weeks revealed impaired glucose tolerance in HFD‐fed mice compared to control diet mice together with IMQ treatment exacerbating the impairment. Accordingly, these data suggest TLR7 activation also exacerbates HFD‐induced dysregulation of glucose handling FVB/N mice, supporting the possibility that endogenous TLR7 activation may contribute to dysglycemia in patients with autoimmune disease.https://doi.org/10.14814/phy2.15949autoimmunityhyperglycemiaimiquimodmetabolic syndrometoll‐like receptor 7
spellingShingle Rahul M. Kakalij
Del L. Dsouza
LiGyeom Ha
Erika I. Boesen
TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
Physiological Reports
autoimmunity
hyperglycemia
imiquimod
metabolic syndrome
toll‐like receptor 7
title TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
title_full TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
title_fullStr TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
title_full_unstemmed TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
title_short TLR7 activation by imiquimod worsens glycemic control in female FVB/N mice consuming a high‐fat diet
title_sort tlr7 activation by imiquimod worsens glycemic control in female fvb n mice consuming a high fat diet
topic autoimmunity
hyperglycemia
imiquimod
metabolic syndrome
toll‐like receptor 7
url https://doi.org/10.14814/phy2.15949
work_keys_str_mv AT rahulmkakalij tlr7activationbyimiquimodworsensglycemiccontrolinfemalefvbnmiceconsumingahighfatdiet
AT delldsouza tlr7activationbyimiquimodworsensglycemiccontrolinfemalefvbnmiceconsumingahighfatdiet
AT ligyeomha tlr7activationbyimiquimodworsensglycemiccontrolinfemalefvbnmiceconsumingahighfatdiet
AT erikaiboesen tlr7activationbyimiquimodworsensglycemiccontrolinfemalefvbnmiceconsumingahighfatdiet